Subclasses of antibodies to hepatitis B core antigen in chronic HBV infection: changes during treatment with alpha interferons and predictors of response

G CHEN, P KARAYIANNIS, M J McGARVEY, A M L LEVER, J A McDONALD, L J SCULLY, S KANATAKIS, AND H C THOMAS

From the Department of Medicine, St Mary's Hospital Medical School, Imperial College of Science, Technology and Medicine, London

SUMMARY  Response to interferon therapy in chronic hepatitis B virus (HBV) carriers is preceded by the appearance of IgM class anti-HBc (antibody to hepatitis B core antigen). The temporal relationship and magnitude of the IgM anti-HBc response is variable suggesting that the antibody is not directly involved in hepatocyte lysis, but is merely a marker of a changed state of immunity to the nucleocapsid proteins, induced by interferon. IgG 1, 2, 3, and 4 class anti-HBc did not change during therapy, but IgG 3 anti-HBc was significantly lower in responders than non-responders. IgG anti-HBc of all subclasses was absent in two Chinese HBV carriers. Lower than normal titres of anti-HBc (p<0.001) were detected in human immunodeficiency virus antibody positive (anti-HIV) HBV carriers. These data indicate the presence of altered immunity to the nucleocapsid antigens in these two types of chronic HBV carrier that are known to respond poorly to antiviral therapy.

IgM antibody plays an important role in immune lysis of infected cells during some acute viral infections, and may also have a role in acute viral hepatitis. IgM anti-HBc is the first antibody appearing soon after HBV infection. In chronic HBV infection, IgM anti-HBc may be persistently present in lower titres.

IgG anti-HBc is also present in both acute and chronic HBV infection and it has been suggested that the binding of non-complement fixing IgG to HBCAg (hepatitis B core antigen) displayed on infected hepatocytes may down modulate T-cell lysis of infected cells. Consistent with this hypothesis is the observation that chimpanzees injected with large quantities of monoclonal antibody to the nucleocapsid proteins at the time of HBV challenge, develop protracted infection. Moreover, cytotoxic T-cells sensitised to both HBCAg and HBCAg displayed in hepatocyte membranes have been demonstrated during acute and chronic HBV infection, and MHC class I antigen expression on hepatocytes has been shown to be enhanced during acute infection.

Thus the balance of antibody and interferon modulation of T-cell lysis of infected cells may determine the efficiency of clearance of the virus.

In this study the sera of HBV carriers undergoing treatment with interferon were examined for changes in titre of total anti-HBc, as well as IgM and IgG subclass distribution. Some of these patients were anti-HIV positive. The data were analysed to try to identify factors which might predict a beneficial response to interferon therapy.

Methods

Patients

Thirty seven consecutive chronic HBV carriers who attended the hepatitis clinic from August 1983 until September 1985 for antiviral treatment with lymphoblastoid interferon were investigated. Their mean age was 36·9 (3·8) years and the duration of their chronic infection was greater than 33·9 (6·4) months. All of them were HBsAg, HBeAg, and HBV-DNA...
positive in serum for at least six months before the start of therapy with interferon. Their mean AST (aspartate transaminase) was 109 (21 SEM) IU/l. All except one patient, had a liver biopsy within three months before the start of treatment and all specimens revealed histologic evidence of chronic hepatitis. Twenty six had chronic active hepatitis (CAH), one chronic persistent hepatitis (CPH), three cirrhosis, and six minimal disease. Only four patients in this trial were anti-HIV positive. In this group of patients both total and IgM anti-HBc determinations were carried out and these were correlated to subsequent seroconversion after interferon treatment. The titres of IgM and/or total anti-HBc given represent the highest ones recorded during the test period.

In order to study more fully the effect of HIV immunosuppression on HBV carriers, sera from patients recruited into another trial were tested for total anti-HBc before start of treatment. From this group of patients 21 of 55 HBV chronic carriers were positive for anti-HIV. All of them were HBsAg, HBeAg, and HBV-DNA positive in serum. Their mean age was 34-7 (range 18–65) and they had a mean AST of 69 (22) IU/l. On liver biopsy 33 had CAH, seven CPH, three chronic lobular hepatitis (CLH), and 12 minimal disease.

No evidence of HDV (hepatitis delta virus) was found in either the serum or the liver of patients investigated in the two studies.

TREATMENT
Patients were treated with 10×10⁸ units/m² of lymphoblastoid interferon (Wellferon, Wellcome Biotechnology) intramuscularly, three times weekly for 12 or 24 weeks. Patients were seen weekly during treatment, and for four weeks after completion of therapy and then at monthly intervals for a further year. Blood samples were taken at each visit and serum was stored at –20°C.

SEROLOGICAL INVESTIGATIONS
Serum specimens were tested for HBsAg by a radioimmunoassay (RIA) utilising murine monoclonal antibodies, HBeAg/anti-HBc, anti-HBs, and anti-HD by commercial RIA (Abbott Laboratories, North Chicago, Ill). Serum HBV-DNA was detected by molecular hybridisation using a ³²P-labelled HBV-DNA probe. Anti-HIV was measured by ELISA (Wellcozyme, Wellcome Diagnostics, Dartford, England). Total anti-HBc was measured by a competitive inhibition ELISA method utilising horseradish peroxidase labelled monoclonal IgG anti-HBc as tracer. Samples were log diluted before testing. The highest dilution still reactive for anti-HBc was taken as the titre. IgM anti-HBc was measured by an ELISA system as described previously. IGG 1, 2, 3, and 4 anti-HBc antibodies were measured by an ELISA system similar to that for IgM anti-HBc, but monoclonal anti-IgG 1, 2, 3, and 4 were used as the capture phase respectively (Serotec, UK). Sera were again log diluted and then tested. Sera negative in the total anti-HBc assay were negative also in the assay for the isotopes of IgG anti-HBc. The highest dilution with a P/N (positive/negative) ratio of >2-1 reactive for anti-HBc was taken as the titre of the relevant subclass IgG anti-HBc.

Results
IgM-ANTI-HBc
Thirty of thirty seven (81%) interferon treated patients with chronic HBV infection were positive for IgM anti-HBc during treatment: six of these were positive before treatment and the remaining 24 became positive one to three weeks after starting treatment. This increased rate of IgM anti-HBc positivity after treatment was highly significant (p<0-001, Table 1).

Three patterns of IgM anti-HBc response were found. The first was of persistently raised titres of IgM anti-HBc during treatment and was noted in 13 patients. Three of these patients were IgM anti-HBc positive before start of treatment. This group of patients was subdivided into two further subgroups depending on the titre of IgM anti-HBc: those with high titres (>1:8000, seven cases) and those with low titres (≤1:8000, six cases). The second group (10 cases), which included the remaining three patients who were positive for IgM anti-HBc before treatment, exhibited fluctuating titres of IgM anti-HBc during treatment. This group was also subdivided into those with high titre (four cases) and low titre (six cases) of IgM anti-HBc. The third group (seven cases) demonstrated a transient presence of IgM anti-HBc, with only one or two samples being positive at low titre. The remaining seven cases were negative.

Table 1 Number of patients positive for IgM anti-HBc before, and number becoming positive during interferon treatment

<table>
<thead>
<tr>
<th></th>
<th>Before treatment</th>
<th>During treatment</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>1–2 weeks</td>
<td>&gt;3 weeks</td>
</tr>
<tr>
<td>Positive (n)</td>
<td>6/37</td>
<td>19/37</td>
<td>5/37</td>
</tr>
<tr>
<td>Positive (%)</td>
<td>16-1</td>
<td>51-4</td>
<td>13-5</td>
</tr>
</tbody>
</table>

χ²=15-93; p<0-001.
for IgM anti-HBc throughout. The relationship of these patterns of IgM anti-HBc to response to interferon are shown in Table 2 and an example of seroconversion in Figure 1.

Table 2  Relationship between presence and absence of IgM anti-HBc, titre of IgM anti-HBc and number of patients seroconverting after treatment with alpha interferon

<table>
<thead>
<tr>
<th>IgM anti-HBc response</th>
<th>Titre</th>
<th>Patients (n)</th>
<th>Seroconverting (n)</th>
<th>p value</th>
<th>Number losing</th>
</tr>
</thead>
<tbody>
<tr>
<td>Persistent</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>all</td>
<td>13</td>
<td>10</td>
<td>&lt;0.01*, =0.001†</td>
<td>7</td>
<td>3</td>
</tr>
<tr>
<td>&gt;1:8000</td>
<td>7</td>
<td>7</td>
<td></td>
<td>4</td>
<td>3</td>
</tr>
<tr>
<td>=1:8000</td>
<td>6</td>
<td>3</td>
<td>=0.05‡</td>
<td>3</td>
<td>0</td>
</tr>
<tr>
<td>Fluctuating</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>all</td>
<td>10</td>
<td>8</td>
<td>&lt;0.01*, =0.001†</td>
<td>1</td>
<td>7</td>
</tr>
<tr>
<td>&gt;1:8000</td>
<td>4</td>
<td>4</td>
<td></td>
<td>1</td>
<td>3</td>
</tr>
<tr>
<td>=1:8000</td>
<td>6</td>
<td>4</td>
<td></td>
<td>0</td>
<td>4</td>
</tr>
<tr>
<td>Transient</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>≤1:8000</td>
<td>7</td>
<td>1</td>
<td>NS‡</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>None</td>
<td>0</td>
<td>7</td>
<td></td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Total</td>
<td>37</td>
<td>19</td>
<td></td>
<td>8</td>
<td>11</td>
</tr>
</tbody>
</table>

*From χ² tests, comparing the number of patients seroconverting to those not seroconverting in the relevant group, with those in the group with transient IgM anti-HBc; †From χ² tests, comparing the number of patients seroconverting to those not seroconverting in the relevant group, with those in whom no IgM anti-HBc was detected; ‡From χ² tests, comparing the number of patients seroconverting to those not seroconverting separated according to the titre of IgM anti-HBc. NS, not significant.

difference in HBV-DNA levels when comparing these between groups. AST levels were lower in the groups without or with transient IgM anti-HBc responses but the differences did not reach statistical significance. There were only four anti-HIV positive patients (one in each group), three of which were non-responders.

**TOTAL ANTI-HBc**

All serum samples tested from the interferon treated patients (except those from two) were positive for total anti-HBc. Titres were greater than 1:100. No change in the titre of total anti-HBc was observed in any of the patients before or during treatment with interferon. The increases in IgM anti-HBc titres described were not evident from the total anti-HBc results.

There were four Chinese patients in this study. Two of these were negative for total anti-HBc in sera taken from the whole period of investigation. Similar results were obtained for IgM anti-HBc and tests for the four IgG subclasses of anti-HBc.

Table 3  IgM anti-HBc response in relation to other prognostic factors that may determine outcome of response to interferon treatment

<table>
<thead>
<tr>
<th>IgM anti-HBc response</th>
<th>HBV-DNA (densiometric units)</th>
<th>AST (IU/L)</th>
<th>HIV Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>Persistent</td>
<td>26.552 (3424)</td>
<td>123 (46-7)</td>
<td>1/13</td>
</tr>
<tr>
<td>Fluctuating</td>
<td>20.261 (2811)</td>
<td>151 (64-5)</td>
<td>1*10</td>
</tr>
<tr>
<td>Transient</td>
<td>26.451 (4264)</td>
<td>97 (31-5)</td>
<td>1/7</td>
</tr>
<tr>
<td>None</td>
<td>24.190 (2135)</td>
<td>73 (24-2)</td>
<td>1/7</td>
</tr>
</tbody>
</table>

*Lost HBeAg but was still anti-HBc negative at the end of follow up. Data are mean (SEM).
Another group of patients with chronic HBV infection entering into a trial of recombinant alpha interferon (55 cases) were studied. These were subdivided into two groups, anti-HIV positive (21) and negative (34). The results of total anti-HBc are shown in Table 4. Four patients were negative and four others were weakly positive for total anti-HBc in the anti-HIV positive group. The mean titre of total anti-HBc in this group was lower than that of the anti-HIV negative group (p<0.001).

Of the 37 treated patients who were initially tested, four were anti-HIV positive. In this small group of anti-HIV positive patients the anti-HBc titres were $10^4$ in one, $10^3$ in two, and $10^2$ in the remaining patient.

**IgG anti-HBc subclasses**

IgG anti-HBc subclasses were studied in sera from seven patients who seroconverted (lost both HBsAg and HBeAg) and 12 without seroconversion to determine whether alterations in the titre of these subclasses were related to the outcome of therapy. These patients were all male, they were anti-HIV negative and all had CAH. Sera before, during, and after treatment with interferon were tested. No obvious changes either in titre or in relative proportions of the IgG anti-HBc subclasses could be found during the course of therapy in the two groups (Fig. 2). All of the sera tested from these patients were positive for the four IgG anti-HBc subclasses. IgG 3 anti-HBc was the dominant subclass in the non-responder group (p<0.01) but did not change during therapy. By contrast in the responding patients IgG 3 anti-HBc was similar in titre to the other IgG subclasses, and once again did not change during therapy. Responders had higher AST levels (p<0.01), slightly lower HBV-DNA levels and a higher incidence of a past history of acute hepatitis (p<0.05).

**Discussion**

During acute type B hepatitis the level of serum HBV-DNA falls as the titre of IgM anti-HBc increases. HBV-DNA levels decrease in patients with chronic HBV infection on interferon therapy and as shown in this study, in seroconverters, this event is also coincident with the appearance of or a rise in the titre of, IgM anti-HBc. Interferon also enhances MHC class I antigen expression on liver cells and it is suggested that this allows the nucleocapsid proteins to be seen by cytotoxic T-cells and lysis of the infected cells follows. Whether the cell-mediated response alone, or type II and III complement dependent mechanisms are also responsible for the lysis of infected cells, is not clear.

The incidence of IgM anti-HBc in HBsAg positive chronic liver disease has varied depending on the group of patients studied and the assays used. In general IgM anti-HBc titres in chronic carriers are considerably lower than in acute hepatitis, they are more often found in patients with CAH (30–43%) than those with CPH (11%) or minimal disease (0–6%); there is a strong relationship with inflammatory activity. In this study 81% of the patients on interferon became positive for IgM anti-HBc and although there existed a close predictive

---

**Table 4**

<table>
<thead>
<tr>
<th>Anti-HIV status</th>
<th>Number with anti-HBc titre of:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>0</td>
</tr>
<tr>
<td>Positive</td>
<td>4</td>
</tr>
<tr>
<td>Negative</td>
<td>0</td>
</tr>
</tbody>
</table>

$\chi^2=15.29; p<0.001$, comparing those with high ($\geq10^3$) and low titre anti-HBc.

**Fig. 2** Comparison of IgG anti-HBc subclasses before, during, and after treatment with interferon. (a) Non-seroconversion and (b) seroconversion groups.
relationship between IgM anti-HBc and seroconversion, the time of the seroconversions did not relate to the time of appearance, duration or titre of IgM anti-HBc. This suggests that the IgM anti-HBc response may not be directly related to clearance of infected cells but merely an indication of induction, by interferon, of the immune response to nucleocapsid proteins. These data suggest that the immunomodulatory effects of interferon may play an important role in eradicating the chronic infection.

In this study we failed to find any correlation between IgG anti-HBc levels and seroconversion on treatment with interferon. IgG 1, 2, 3, and 4 subclasses of anti-HBc were constant in titre and in relative proportions. Trevisan et al. reported that the eluted immunoglobulins from membranes of HBV infected hepatocytes were restricted to IgG 1 and IgG 3 subclasses, and that a specific titre of HBCAg. Our data show that there is no lack of IgG 2 and IgG 4 anti-HBc in serum and the reason for these antibodies not being detected in the membrane eluate is unclear. The titre of IgG 3 anti-HBc was significantly higher than the other subclasses (p<0.1) in the group not seroconverting during therapy. IgG 3 antibody appears to relate to the duration of infection, and therefore the higher titre of IgG 3 anti-HBc in non-responders may merely reflect the duration of HBV infection.

Two Chinese patients were negative for anti-HBc. Low anti-HBc titres are more frequent in patients with liver cirrhosis, but rare in healthy carriers and patients with CAH or CPH. Both of our patients with absent anti-HBc responses were healthy carriers with normal AST and liver histology. This total absence of anti-HBc in HBsAg/HBeAg positive patients suggests a state of tolerance to HBCAg. Whether this has arisen because of infection in utero or is related to genetic factors is unclear. These patients did not produce IgM anti-HBc during therapy and did not respond.

Low titres or absence of anti-HBc were also found in eight patients with anti-HIV antibody, and only a few showed an IgM anti-HBc response after starting interferon treatment. This suggests a deficiency in specific humoral immune responses even though immunoglobulins are increased. The majority of the eight patients without any anti-HBc or low levels of this antibody had more clinical features of HIV infection (four had generalised lymphadenopathy, one had Pneumocystis carinii pneumonia and one other Kaposi’s sarcoma) than the 13 patients who were anti-HIV positive and had normal levels of anti-HBc. Thus in HIV infected individuals, a falling anti-HBc titre may be of prognostic value and further prospective studies will be needed to address this issue.

M McGarvey and A M L Lever are supported by the Wellcome Trust.

References

13 Karayiannis P, Fowler MJF, Lok ASF, Greenfield C.
Chen, Karayiannis, McGarvey, Lever, McDonald, Scully, Kanatakis, and Thomas


